AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03747055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group problem management plus
Description: Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
Study NCT01233258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) on demand
Description: Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
Study NCT01233258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis low-dose
Description: Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Study NCT03747055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced treatment as usual
Description: Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
Study NCT01233258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII (BAY81-8973) prophylaxis high-dose
Description: Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
Study NCT02572401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAND HIV Risk Reduction Intervention
Description: STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
Study NCT02572401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Intervention
Description: Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
Study NCT00853775 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Study NCT04660305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT278
Description: Concentrated rapid acting insulin aspart
Study NCT04660305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT278
Description: Concentrated rapid acting insulin aspart
Study NCT04660305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovoRapid
Description: Rapid acting insulin aspart
Study NCT04660305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NovoRapid
Description: Rapid acting insulin aspart
Study NCT01406743 — intervention group
Intervention type: DEVICE
Intervention: EOS™ Acquisition
Description: Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
Study NCT04623112 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hearing aid feature: Frequency Compression
Description: FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
Study NCT04623112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid feature: Frequency Compression
Description: FC Deactivated/Activated \& set to default/Activated \& set to hearing loss
Study NCT03812107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Treatment Approach
Description: The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
Study NCT01271179 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sequential perfusion with ipv Ross solution and UW solution
Description: Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
Study NCT00807144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kidney transplant maintenance immunosuppression
Description: Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
Study NCT03812107 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Treatment Approach
Description: After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
Study NCT03975036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib Hydrochloride Capsules
Study NCT00648349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium Delayed-Release Tablets 20 mg
Description: 20mg, single dose fasting
Study NCT01271179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sole perfusion with UW solution
Description: Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
Study NCT04269733 — intervention group
Intervention type: DEVICE
Intervention: Right ventricular pacing
Description: Right ventricular pacing from a DDD pacemaker implanted due to high-degree AV block
Study NCT00536484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: 4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Study NCT00536484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
Study NCT01633502 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional circulatory support
Description: Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
Study NCT01633502 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impella CP
Description: Control group treated with Impella CP for a minimum of 48 hrs.
Study NCT02434224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: 2 to 3 sessions per week of individualized creative music therapy
Study NCT01370213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preparative Regimen
Description: Preparative Regimen:~1) fludarabine 40 mg/m\^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,
Study NCT01370213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: CD3\^- CD19\^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
Study NCT03975036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 antibody
Description: Pembrolizumabinjection
Study NCT01370213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
Study NCT01370213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Graft/Anti-thymocyte globulin
Description: Single donor filgrastim mobilized CD34+ selected peripheral blood stem cell graft (minimum cell dose of 5 x 10\^6/kg) on day 0. Rabbit anti-thymocyte globulin (ATG) will be administered on day -1 (0.5 mg/kg) and day +1 and +2 (2.5 mg/kg) pretransplant per institutional guidelines. ATG dosing not identical for all patients.
Study NCT01370213 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor TCR α/β-depleted Graft/ATG
Description: Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10\^6/kg) on day 0. ATG will be administered on days -6 and -5 (3mg/kg) for most patients.
Study NCT03892213 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Description: Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9\*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12\* until Day 15.
Study NCT03892213 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: E1224
Description: E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly.
Study NCT04016337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverages
Description: The beverages were all made with lemon and maqui extracts, and different sweeteners
Study NCT00925301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat hydrochloride
Description: Oral capsule QOD
Study NCT00925301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule QOD
Study NCT02373670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of positive deviance behaviors
Description: Using locally derived positive deviance findings to inform a behavioral intervention
Study NCT02373670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Promotion of healthy behaviors
Description: Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
Study NCT04816630 — intervention group
Intervention type: DEVICE
Intervention: CBC-Diff Monocyte Volume Width Distribution
Description: MDW is part of the CBC-Diff and will be collected but not reported to the physician. MDW will not impact standard of care.
Study NCT02191475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glycopeptide plus carbapenem
Description: The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
Study NCT02191475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haizheng Li Xing ® plus tazocin ®
Description: Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
Study NCT03347552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME
Description: Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care.
Study NCT01685541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maximum After Visit Summary Content
Study NCT01685541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate After Visit Summary Content
Study NCT01095211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-vitamin complex
Description: 5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
Study NCT00648349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex® Delayed-Release Tablets 20 mg
Description: 20mg, single dose fasting
Study NCT01095211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B-vitamin complex
Description: 5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
Study NCT05948644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: TPN171H 2.5mg TPN171H 5mg TPN171H 10mg
Study NCT02378597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Resiliency Intervention
Description: 4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
Study NCT02256995 — intervention group
Intervention type: DEVICE
Intervention: uChek
Description: The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
Study NCT00637351 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: One blood sample will be collected at the time of screening for subjects
Study NCT00637351 — intervention group
Intervention type: PROCEDURE
Intervention: Urine sample
Description: One urine sample will be collected at the time of screening for subjects
Study NCT01685541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimum After Visit Summary Content
Study NCT01685541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual AVS
Study NCT02513836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-education intervention
Description: All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
Study NCT02513836 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-education intervention
Description: All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
Study NCT01567722 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Description: This sample will be used for germline DNA analysis.
Study NCT01567722 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Description: RNA will be sheared, reverse transcribed, and sequenced to assess transcribed sequences.
Study NCT01567722 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Description: Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
Study NCT01567722 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Description: Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
Study NCT01567722 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Genomic analyses performed on these samples may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies, as well as whole genome sequencing analysis using the most current genomic technology available.
Study NCT01567722 — intervention group
Intervention type: OTHER
Intervention: flow cytometry
Description: Information will include HIV RNA load at time of malignancy diagnosis) and imaging tests, results of the diagnostic tumor biopsy and bone marrow biopsy, and results of flow cytometry, cytogenetics, and molecular studies.
Study NCT01567722 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Participants will be followed prospectively to record the types of treatment given, and treatment outcome and toxicity.
Study NCT02657148 — intervention group
Intervention type: DRUG
Intervention: Nexplanon (etonogestrel contraceptive implant)
Description: Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
Study NCT02657148 — intervention group
Intervention type: DRUG
Intervention: Standard postpartum contraceptive care
Description: Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
Study NCT03179878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03179878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1020
Description: Investigational Product
Study NCT00329043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Agonist
Description: Intramuscular injection either monthly for 3 months or in a single 3-month dose.
Study NCT00329043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: 25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
Study NCT00329043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Radical prostatectomy after completion of Sunitinib and LHRH agonist.
Study NCT03234634 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular thrombectomy
Description: Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~1. Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~2. Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
Study NCT00897026 — intervention group
Intervention type: DRUG
Intervention: cyclophosphamide
Study NCT00897026 — intervention group
Intervention type: DRUG
Intervention: doxorubicin hydrochloride
Study NCT00897026 — intervention group
Intervention type: DRUG
Intervention: paclitaxel
Study NCT00897026 — intervention group
Intervention type: GENETIC
Intervention: fluorescence in situ hybridization
Study NCT00897026 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study NCT01470157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 5mg/kg as oral suspension
Study NCT01470157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
Study NCT02170064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093 (Eslicarbazepine acetate)
Description: Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
Study NCT04211363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast 0.3% cream
Description: Roflumilast 0.3% cream for topical application.
Study NCT04211363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream for topical application.
Study NCT04850326 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AP green tea extract
Description: single intake of AP green tea extract
Study NCT04660734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractures of the posterior structures of the acetabulum treated by fixation using the Kocher-Langenbeck approach.
Description: Fracture fixation of posterior structures of acetabulum by using the surgical procedure of Kocher-Langenbeck approach
Study NCT02144467 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: fMRI, sMRI, ASL and DTI